Results 181 to 190 of about 7,325 (251)

Inosine triphosphate pyrophosphatase activity as a potential predictor of methotrexate remission in juvenile idiopathic arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Background Methotrexate (MTX) is the first‐line therapy for juvenile idiopathic arthritis (JIA), but up to 40% of patients don't respond. Low inosine‐triphosphate‐pyrophosphatase (ITPA) activity has been associated with reduced clinical remission. We investigated ITPA role and the underlying mechanisms in vitro.
Sofia Sindici Forgiarini   +19 more
wiley   +1 more source

Multi‐omic profiling reveals immune cell priming signature linked to lupus prognosis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is a multi‐organ disease with widespread immune dysregulation and significant unmet clinical need. Blood‐based gene expression studies have advanced our understanding of SLE pathogenesis but may overlook critical tissue‐specific mechanisms that drive disease heterogeneity and progression.
Michael A. Smith   +23 more
wiley   +1 more source

A Micro-Nodal Tungsten-Rhenium Thin-Film Thermocouple Based on Electrohydrodynamic Printing. [PDF]

open access: yesMaterials (Basel)
Hu S   +9 more
europepmc   +1 more source

TWEAK/Fn14 signaling drives oxidative cardiac injury in systemic lupus erythematosus: Evidence from patient biomarker studies, lupus mouse models, and cardiomyocyte assays

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Cardiac involvement is a major cause of morbidity in systemic lupus erythematosus (SLE). Tumor necrosis factor–like weak inducer of apoptosis (TWEAK) is elevated in SLE, but its contribution to lupus‐associated cardiac injury is unclear. We investigated the role of TWEAK/Fn14 signaling in SLE‐related cardiomyopathy and its potential as a ...
Yale Liu   +12 more
wiley   +1 more source

Synthesis of a <i>fac</i>-Tricarbonylrhenium(I) Complex with Pyrithione, Its Physicochemical Characterization, and Assessment of Biological Effects. [PDF]

open access: yesACS Omega
Rapuš U   +10 more
europepmc   +1 more source

Single‐cell level characterization of B cell depletion and repopulation following rituximab in systemic lupus erythematosus

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang   +9 more
wiley   +1 more source

Rhenium

open access: yesMetal Powder Report, 2001
openaire   +1 more source

Home - About - Disclaimer - Privacy